MiR-532-3p Inhibits Proliferation and Promotes Apoptosis of Lymphoma Cells by Targeting β-Catenin
Affiliations
Dysregulated expression of miR-532-3p has been observed in several types of cancer and plays a key role in tumor progression and metastasis. In this study, we analyzed the role and molecular mechanism of miR-532-3p in lymphoma progression. The expression of miR-532-3p in lymphoma sample tissues was analyzed using the GEO database and in cell lines by quantitative reverse transcription (qRT)-PCR. The functions of miR-532-3p in lymphoma cell proliferation and apoptosis were analyzed by CCK-8 assay and Annexin V-FITC/propidium iodide staining, respectively. , the tumor weight and volume were measured. The target gene of miR-532-3p was predicted using miRanda software, and then luciferase, qRT-PCR, and western blot assays were performed to verify that β-catenin was the downstream target gene of miR-532-3p. miR-532-3p was decreased in lymphoma tissues and cell lines. and experiments showed that overexpression of miR-532-3p inhibited lymphoma cell proliferation and promoted apoptosis. Mechanistic studies demonstrated that β-catenin was a functional target gene of miR-532-3p. Furthermore, we found that overexpression of β-catenin reversed the tumor-suppression activities caused by overexpression of miR-532-3p in lymphoma proliferation and apoptosis. This study demonstrates that miR-532-3p functions as a tumor inhibitor in lymphoma progression by targeting β-catenin, suggesting miR-532-3p/β-catenin as a new diagnosis marker or potential therapeutic target in lymphoma.
Dai W, Pang S, He Z, Fu X, Liu L, Liu L Health Inf Sci Syst. 2024; 13(1):4.
PMID: 39659869 PMC: 11625705. DOI: 10.1007/s13755-024-00319-1.
Mahajan K, Das A, Alahari S, Pothuraju R, Nair S Cancers (Basel). 2024; 16(17).
PMID: 39272919 PMC: 11394065. DOI: 10.3390/cancers16173061.
Yao G, Fu L, Dai J, Chen J, Liu K, Liang H J Transl Med. 2024; 22(1):596.
PMID: 38926764 PMC: 11209967. DOI: 10.1186/s12967-024-05290-9.
Epigenetic alterations and advancement of lymphoma treatment.
Zhuang S, Yang Z, Cui Z, Zhang Y, Che F Ann Hematol. 2023; 103(5):1435-1454.
PMID: 37581713 DOI: 10.1007/s00277-023-05395-z.
Afonso G, Cavaleiro C, Valero J, Mota S, Ferreiro E Cells. 2023; 12(13).
PMID: 37443797 PMC: 10340215. DOI: 10.3390/cells12131763.